Thyroid Carcinoma Clinical Trial
Official title:
Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma.
Correlation analysis between estimated renal function and biological half life of 131-I during radioiodine treatment of patients with differentiated thyroid cancer.
131-I during radioiodine treatment of patients with differentiated thyroid cancer is mainly renally excreted. It is advised in the clinical guidelines that serum creatinine should be determined before applying 131-I and if necessary the administered dose should be reduced. Nevertheless no guideline gives advice in what extent the dose should be decreased. The adjustment is at the discretion of the attending physician. Aim of this prospective study is to correlate the biological half life of 131-I with the renal function to give objective recommendations concerning the reduction of the applied dose in patients with limited renal function. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
| Withdrawn |
NCT01707056 -
The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma
|
N/A | |
| Completed |
NCT00215605 -
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
| Terminated |
NCT04327999 -
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
|
Phase 2 | |
| Completed |
NCT02194920 -
Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function
|
N/A | |
| Enrolling by invitation |
NCT06095362 -
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
|
Phase 1 | |
| Not yet recruiting |
NCT05949424 -
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
|
Phase 4 | |
| Active, not recruiting |
NCT02145143 -
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
|
N/A | |
| Terminated |
NCT01865838 -
A Study Into the Effect of Seprafilm in Open Total Thyroidectomy
|
N/A | |
| Recruiting |
NCT00749697 -
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
|
N/A | |
| Enrolling by invitation |
NCT04411290 -
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
|
||
| Completed |
NCT01813136 -
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
| Active, not recruiting |
NCT02185560 -
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
|
||
| Completed |
NCT04462471 -
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
|
Phase 1 | |
| Completed |
NCT01433809 -
Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm
|
N/A | |
| Recruiting |
NCT00929318 -
Influence of Thyroid Hormones on the Woundhealing Process
|
N/A | |
| Completed |
NCT05178186 -
Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer
|
N/A | |
| Completed |
NCT01013597 -
Trial of LBH589 in Metastatic Thyroid Cancer
|
Phase 2 |